Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both von Koschmieder, S, Mughal, T I, Hasselbalch, H C, Barosi, G, Valent, P, Kiladjian, J-J, Jeryczynski, G, Gisslinger, H, Jutzi, J S, Pahl, H L, Hehlmann, R, Maria Vannucchi, A, Cervantes, F, Silver, R T, Barbui, T

Volltext

The calreticulin (CALR) exon 9 mutations are promising targets for cancer immune therapy von Holmström, M O, Martinenaite, E, Ahmad, S M, Met, Ö, Friese, C, Kjær, L, Riley, C H, thor Straten, P, Svane, I M, Hasselbalch, H C, Andersen, M H

Volltext

Early detection of myeloproliferative neoplasms in a Danish general population study von Cordua, S., Kjaer, L., Skov, V., Pallisgaard, N., Kefala, M., Gjerdrum, L. M. R., Hasselbalch, H. C., Ellervik, C.

Volltext

COVID-19 as a mediator of interferon deficiency and hyperinflammation: Rationale for the use of JAK1/2 inhibitors in combination with interferon von Hasselbalch, H.C., Skov, V., Kjær, L., Ellervik, C., Poulsen, A., Poulsen, T.D., Nielsen, C.H.

Volltext

The CALR exon 9 mutations are shared neoantigens in patients with CALR mutant chronic myeloproliferative neoplasms von Holmström, M O, Riley, C H, Svane, I M, Hasselbalch, H C, Andersen, M H

Volltext

Prevalence and clinical significance of neutropenia discovered in routine complete blood cell counts: a longitudinal study von Andersen, C. L., Tesfa, D., Siersma, V. D., Sandholdt, H., Hasselbalch, H., Bjerrum, O. W., Felding, P., Lind, B., Olivarius, Niels de. F., Palmblad, J.

Volltext

The JAK2V617F mutation is a target for specific T cells in the JAK2V617F-positive myeloproliferative neoplasms von Holmström, M O, Hjortsø, M D, Ahmad, S M, Met, Ö, Martinenaite, E, Riley, C, Straten, P, Svane, I M, Hasselbalch, H C, Andersen, M H

Volltext

Antibodies to calnexin and mutated calreticulin are common in human sera von Kyllesbech, C, Trier, N, Mughal, F, Hansen, P, Holmström, M, el Fassi, D, Hasselbalch, H, Skov, V, Kjær, L, Andersen, M, Ciplys, E, Slibinskas, R, Frederiksen, J, Højrup, P, Houen, G

Volltext

Characterization of blood donors with high haemoglobin concentration von Magnussen, K., Hasselbalch, H. C., Ullum, H., Bjerrum, O. W.

Volltext

Inheritance of the chronic myeloproliferative neoplasms. A systematic review von Ranjan, A, Penninga, E, Jelsig, AM, Hasselbalch, HC, Bjerrum, OW

Volltext

Distinguishing myelofibrosis from polycythemia vera and essential thrombocythemia: The utility of enumerating circulating stem cells with aberrant hMICL expression by flow cytometr... von Herborg, L. L., Nederby, L., Hasselbalch, H. C., Aggerholm, A., Roug, A. S.

Volltext

Quantitative assessment of the JAK2 V617F allele burden: equivalent levels in peripheral blood and bone marrow von Larsen, T S, Pallisgaard, N, Møller, M B, Hasselbalch, H C

Volltext

A unified definition of clinical resistance intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group von BAROSI, G, BESSES, C, HASSELBALCH, H, LENGFELDER, E, REILLY, J. T, MICHIELS, J. J, BARBUI, T, BIRGEGARD, G, BRIERE, J, CERVANTES, F, FINAZZI, G, GISSLINGER, H, GRIESSHAMMER, M, GUGLIOTTA, L, HARRISON, C

Volltext

S196: ROPEGINTERFERON ALFA‐2B ACHIEVES PATIENT‐SPECIFIC TREATMENT GOALS IN POLYCYTHEMIA VERA: FINAL RESULTS FROM THE PROUD‐PV/CONTINUATION‐PV STUDIES von Gisslinger, H., Klade, C., Georgiev, P., Krochmalczyk, D., Gercheva‐Kyuchukova, L., Egyed, M., Dulicek, P., Illes, A., Pylypenko, H., Sivcheva, L., Mayer, J., Yablokova, V., Empson, V., Krejcy, K., Hasselbalch, H., Kralovics, R., Kiladjian, J.‐J.

Volltext

Combination therapy with interferon and JAK1-2 inhibitor is feasible: Proof of concept with rapid reduction in JAK2V617F-allele burden in polycythemia vera von Bjørn, M.E., de Stricker, K., Kjær, L., Ellemann, K., Hasselbalch, H.C.

Volltext

Systemic adverse events following rituximab therapy in patients with Graves’ disease von El Fassi, D., Nielsen, C. H., Junker, P., Hasselbalch, H. C., Hegedüs, L.

Volltext

Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET) von Barosi, Giovanni, Bordessoule, Dominique, Briere, Jean, Cervantes, Francisco, Demory, Jean-Loup, Dupriez, Brigitte, Gisslinger, Heinz, Griesshammer, Martin, Hasselbalch, Hans, Kusec, Rajko, Le Bousse-Kerdiles, Marie-Caroline, Liberato, Nicola L., Marchetti, Monia, Reilly, John T., Thiele, Jurgen

Volltext

Increased platelet activation and abnormal membrane glycoprotein content and redistribution in myeloproliferative disorders von Jensen, Morten Krogh, De Nully Brown, Peter, Lund, Birgit Villadsen, Nielsen, Ove Juul, Hasselbalch, Hans Carl

Volltext

FRI0113 Rheumatoid arthritis and eosinophilia: the risk of lymphoproliferative malignancies and solid cancers. a study based on the copenhagen primary care differential count (copd... von Lykkegaard Andersen, C., Vestergaard, H., Bjerrum, O. W., Siersma, V. D., Felding, P., Hasselbalch, H., de Fine Olivarius, N., Lindegaard, H. M.

Volltext

Cytokine Profiling as a Novel Complementary Tool to Predict Prognosis in MPNs? (vol 4, e407, 2020) von Hasselbalch, H. C.

Volltext